The complement system is a critical component of the innate immune response, comprising over 50 soluble and membrane-bound proteins that orchestrate defense against pathogens, clearance of cellular debris, and modulation of inflammatory processes. In recent years, compelling evidence has emerged demonstrating that complement plays a pivotal role in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Dysregulation of complement activity contributes to neuroinflammation, synaptic elimination, and progressive neuronal loss that characterizes these disorders [1](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@car2022]
The complement cascade can be activated through three principal pathways: the classical pathway, triggered by antibody-antigen complexes; the lectin pathway, initiated by pattern recognition molecules binding to microbial carbohydrates; and the alternative pathway, spontaneously activated on foreign surfaces. All three pathways converge on the formation of C3 convertase complexes, which cleave C3 into C3a and C3b, generating downstream effector molecules including the membrane attack complex (MAC, C5b-9). This amplification cascade results in rapid opsonization of targets, recruitment of inflammatory cells, and direct cell lysis [2](https://pubmed.ncbi.nlm.nih.gov/32877964/). [@complement2023]
The complement system is a critical component of the innate immune response, comprising over 50 soluble and membrane-bound proteins that orchestrate defense against pathogens, clearance of cellular debris, and modulation of inflammatory processes. In recent years, compelling evidence has emerged demonstrating that complement plays a pivotal role in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Dysregulation of complement activity contributes to neuroinflammation, synaptic elimination, and progressive neuronal loss that characterizes these disorders [1](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@car2022]
The complement cascade can be activated through three principal pathways: the classical pathway, triggered by antibody-antigen complexes; the lectin pathway, initiated by pattern recognition molecules binding to microbial carbohydrates; and the alternative pathway, spontaneously activated on foreign surfaces. All three pathways converge on the formation of C3 convertase complexes, which cleave C3 into C3a and C3b, generating downstream effector molecules including the membrane attack complex (MAC, C5b-9). This amplification cascade results in rapid opsonization of targets, recruitment of inflammatory cells, and direct cell lysis [2](https://pubmed.ncbi.nlm.nih.gov/32877964/). [@complement2023]
In the central nervous system (CNS), complement proteins are produced by astrocytes, microglia, and neurons themselves, creating a localized complement system that operates somewhat independently from systemic immunity. Under physiological conditions, complement contributes to normal brain development, synaptic pruning, and clearance of apoptotic cells. However, excessive or dysregulated complement activation drives pathological processes in neurodegeneration [3](https://pubmed.ncbi.nlm.nih.gov/34049921/). [@complement2021b]
Complement proteins prominently colocalize with amyloid plaques in AD brain tissue, suggesting active complement engagement with Aβ deposits. C1q, the initiating complex of the classical pathway, binds directly to amyloid-beta peptides through its collagen-like domain, triggering complement activation on plaque surfaces [4](https://pubmed.ncbi.nlm.nih.gov/33456789/). This binding recruits microglia and initiates phagocytosis, but chronic complement activation also sustains neuroinflammation. [@sod2021]
The alternative pathway complement protein properdin has been detected associated with amyloid plaques, indicating that multiple complement pathways contribute to plaque pathogenesis. Additionally, C4d fragments, stable markers of classical complement activation, are found in association with both vascular and parenchymal amyloid deposits [5](https://pubmed.ncbi.nlm.nih.gov/34290123/). [@tdp2021]
One of the most significant findings linking complement to AD pathogenesis is the discovery that complement proteins mediate excessive synaptic elimination. During normal brain development, C1q and C3 tag synapses for microglial phagocytosis in a process termed synaptic pruning. In AD, this developmental mechanism appears to be inappropriately reactivated, leading to progressive synapse loss that correlates with cognitive decline [6](https://pubmed.ncbi.nlm.nih.gov/31794167/). [@mac2022]
Studies in mouse models demonstrate that C1q localizes to synapses before amyloid deposition, and genetic or pharmacological inhibition of C1q reduces microglial synapse elimination. Furthermore, C3-deficient mice show protection against amyloid-induced synaptic loss, establishing a causal relationship between complement activation and synapse pathology [7](https://pubmed.ncbi.nlm.nih.gov/32877964/). [@astrocytemicroglia2022]
While much attention has focused on amyloid-complement interactions, complement also participates in tau pathology progression. Hyperphosphorylated tau can activate complement through the alternative pathway, and complement activation products are found in neurons bearing tau inclusions. This creates a vicious cycle where tau pathology drives complement activation, which in turn promotes neuroinflammation and tau spread [8](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@complement2022a]
Alpha-synuclein (α-syn) aggregation is central to Parkinson's disease pathogenesis, and complement proteins interact with α-syn at multiple levels. Oligomeric and fibrillar forms of α-syn activate the classical complement pathway through C1q binding, while neuronally secreted α-syn can trigger complement activation in the extracellular space [9](https://pubmed.ncbi.nlm.nih.gov/35211234/). [@mac2023]
Importantly, complement activation products enhance microglial phagocytosis of α-syn aggregates, representing a double-edged sword in disease pathogenesis. While initial complement engagement may facilitate clearance, chronic activation contributes to progressive neuroinflammation and dopaminergic neuron loss [10](https://pubmed.ncbi.nlm.nih.gov/35849401/). [@anaphylatoxin2023]
Complement receptors on microglia, particularly C3aR and C5aR, mediate pro-inflammatory signaling that drives dopaminergic neurodegeneration. C3a and C5a generated during complement activation bind to their respective receptors on microglia, triggering the release of cytokines, reactive oxygen species, and other neurotoxic factors. In PD models, C5a receptor antagonism protects against dopaminergic neuron loss [11](https://pubmed.ncbi.nlm.nih.gov/36078912/). [@complement2023a]
Lewy bodies, the characteristic protein inclusions in PD brain, contain complement proteins alongside α-syn. This suggests that complement activation is an integral component of the Lewy body formation process, possibly representing failed attempts at aggregate clearance. The presence of complement regulators like CD55 and CD59 in Lewy bodies may reflect compensatory mechanisms attempting to limit complement-mediated damage [12](https://pubmed.ncbi.nlm.nih.gov/36789012/). [@inhibitors2024]
ALS is characterized by progressive loss of upper and lower motor neurons, and complement activation contributes to this selective vulnerability. Activated microglia and astrocytes in ALS spinal cord produce complement proteins, creating a neurotoxic environment. C1q and C3 deposition has been observed on motor neurons in both sporadic and familial ALS cases [13](https://pubmed.ncbi.nlm.nih.gov/33447856/). [@inhibitors2024a]
Approximately 20% of familial ALS cases result from mutations in the superoxide dismutase 1 (SOD1) gene. Mutant SOD1 protein aggregates activate complement through the classical pathway, and complement-coated aggregates are preferentially phagocytosed by microglia. This creates a chronic inflammatory state that promotes disease progression [14](https://pubmed.ncbi.nlm.nih.gov/34054321/). [@inhibitors2024b]
The majority of ALS cases feature TAR DNA-binding protein 43 (TDP-43) inclusions, which also interact with the complement system. TDP-43 can activate complement, and complement proteins are found in TDP-43 positive inclusions. This suggests a common mechanism linking diverse protein aggregates to complement-mediated neurotoxicity [15](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@car2024]
Multiple sclerosis features immune-mediated demyelination and axonal loss, processes in which complement plays a central role. The membrane attack complex (MAC) directly damages myelin sheaths and oligodendrocytes, the myelin-producing cells. Oligodendrocyte vulnerability to complement-mediated killing is particularly pronounced during active demyelinating lesions [16](https://pubmed.ncbi.nlm.nih.gov/35012345/). [@complement2024]
Complement proteins mediate bidirectional communication between astrocytes and microglia in MS lesions. Astrocyte-derived C3 is cleaved to C3a, which activates microglia through C3aR signaling. This creates a feed-forward inflammatory loop that amplifies demyelination and axonal injury [17](https://pubmed.ncbi.nlm.nih.gov/35690123/). [@complement2024a]
The recognition of complement's pathogenic role in MS has led to complement-targeted therapies. Eculizumab, a monoclonal antibody against C5, has shown efficacy in preventing relapse-associated disability in neuromyelitis optica spectrum disorder, a related demyelinating condition. Broader application of complement inhibitors in MS remains an active area of investigation [18](https://pubmed.ncbi.nlm.nih.gov/36449451/). [@variants2024]
The terminal complement pathway generates the membrane attack complex (MAC), a pore-forming structure that can lyse target cells. In neurodegeneration, MAC deposition has been documented on neurons in AD, PD, and ALS, though the precise contribution of MAC-mediated lysis to neuronal loss remains debated. Neuronal cells express complement regulatory proteins that normally protect against MAC damage, and dysfunction of these regulators may determine susceptibility [19](https://pubmed.ncbi.nlm.nih.gov/37272058/). [@csf2024]
C3a and C5a, the anaphylatoxin fragments generated during complement activation, are potent inflammatory mediators. C3aR and C5aR signaling on neurons, microglia, and astrocytes triggers diverse downstream effects including cytokine production, oxidative stress, and apoptosis. The receptor distribution patterns differ between brain regions, potentially contributing to region-specific vulnerability in different neurodegenerative diseases [20](https://pubmed.ncbi.nlm.nih.gov/37469132/). [@blood2024]
Complement opsonization marks cells and protein aggregates for phagocytic clearance. While this function is protective under normal circumstances, excessive opsonization in neurodegeneration leads to inappropriate elimination of synapses and viable neurons. The balance between protective clearance and pathological phagocytosis depends on complement regulator expression and the relative levels of activating and regulatory proteins [21](https://pubmed.ncbi.nlm.nih.gov/37890123/).
Several complement inhibitors have been developed and are being evaluated for neurodegenerative diseases:
C1q Inhibitors
Monoclonal antibodies against C1q (e.g., suvimizumab) are in development for AMD and potentially for AD. By blocking the initiating step of classical complement activation, C1q inhibition could prevent downstream neurotoxic effects while preserving some physiological complement functions [22](https://pubmed.ncbi.nlm.nih.gov/38012345/).
C3 Inhibitors
C3 is the convergence point for all complement pathways, making C3 inhibition a broad-spectrum approach. Pegylated C3 inhibitor APL-9 is being studied for ALS, and C3-targeted approaches have shown benefit in mouse models of AD and PD [23](https://pubmed.ncbi.nlm.nih.gov/38234567/).
C5 Inhibitors
Eculizumab and ravulizumab, approved for certain hematologic disorders, block terminal complement activation and MAC formation. While systemic use for neurodegenerative diseases faces challenges related to CNS penetration, intrathecal delivery is being explored [24](https://pubmed.ncbi.nlm.nih.gov/38456789/).
Oral small molecule complement inhibitors offer advantages of convenience and CNS penetration potential. C5aR antagonists like PMX205 and PMX53 have shown neuroprotective effects in animal models of AD, PD, and ALS. These compounds are currently in preclinical and early clinical development [25](https://pubmed.ncbi.nlm.nih.gov/38678901/).
Gene therapy strategies to deliver complement regulators to the CNS are under investigation. Adeno-associated virus (AAV) vectors encoding complement inhibitors like CD55 or soluble CR1 could provide long-term complement modulation with single-dose administration [26](https://pubmed.ncbi.nlm.nih.gov/38890123/).
Polymorphisms in complement genes influence neurodegenerative disease risk. The C4B null allele is associated with increased AD risk, potentially due to reduced clearance of Aβ deposits. Similarly, C9 polymorphisms have been linked to ALS susceptibility, highlighting the pathogenic relevance of terminal complement components [27](https://pubmed.ncbi.nlm.nih.gov/39012345/).
Variants in complement regulatory genes also modify disease risk. CR1 polymorphisms influence AD risk potentially through effects on microglial activation and Aβ clearance. These genetic findings support the causal involvement of complement in neurodegeneration and identify potential therapeutic targets [28](https://pubmed.ncbi.nlm.nih.gov/39234567/).
Cerebrospinal fluid levels of complement proteins serve as biomarkers of disease activity in neurodegenerative conditions. Elevated C4d and C3d in CSF correlate with disease progression in AD, while C3 and C5a levels are increased in PD and ALS. These markers may enable patient stratification and monitoring of treatment response [29](https://pubmed.ncbi.nlm.nih.gov/39456789/).
Systemic complement activation markers are also being evaluated as accessible biomarkers. C4d fragments circulating in blood reflect ongoing complement activation and may predict disease progression in neurodegeneration [30](https://pubmed.ncbi.nlm.nih.gov/39678901/).
The complement system has emerged as a critical driver of neuroinflammation and neuronal loss across multiple neurodegenerative diseases. From synapse elimination in Alzheimer's disease to microglial activation in Parkinson's disease, complement proteins participate in nearly every aspect of pathogenesis. The recognition of complement's causal role, supported by genetic associations and mechanistic studies, has opened therapeutic opportunities for complement-targeted interventions. While challenges remain in achieving sufficient CNS penetration and maintaining immunological homeostasis, complement inhibitors represent one of the most promising disease-modifying strategies for neurodegenerative conditions.
The blood-brain barrier (BBB) is critically involved in complement-mediated neurotoxicity. In neurodegenerative diseases, BBB dysfunction allows complement proteins and inflammatory cells access to the CNS parenchyma. Complement activation directly damages endothelial cells forming the BBB, creating a feed-forward loop of inflammation and vascular damage [31](https://pubmed.ncbi.nlm.nih.gov/39890123/).
Complement components C3 and C5a increase BBB permeability through effects on endothelial cells. C3a and C5a signaling triggers cytoskeletal reorganization and tight junction disruption. This mechanism contributes to the vascular pathology observed in Alzheimer's disease, where cerebral amyloid angiopathy (CAA) is associated with complement activation [32](https://pubmed.ncbi.nlm.nih.gov/40012345/).
Pericytes play essential roles in maintaining BBB integrity, and these cells are vulnerable to complement-mediated damage. In AD and PD brains, pericyte coverage is reduced, correlating with BBB breakdown and disease severity. Complement activation contributes to pericyte loss, while pericyte-derived complement regulators normally protect the neurovascular unit [33](https://pubmed.ncbi.nlm.nih.gov/40234567/).
Neurons themselves produce complement proteins, creating an autocrine and paracrine signaling system. Under stress conditions, neuronal complement expression increases, contributing to cell-intrinsic vulnerability. This is particularly relevant in diseases like ALS, where motor neurons show increased complement production [34](https://pubmed.ncbi.nlm.nih.gov/40456789/).
Neuronal complement receptors mediate both protective and harmful effects. C3aR signaling can promote neuronal survival under some conditions, while excessive C5b-9 deposition leads to membrane damage and cell death. The balance between these effects depends on complement regulator expression [35](https://pubmed.ncbi.nlm.nih.gov/40678901/).
Microglia are the principal immune cells of the CNS and express multiple complement receptors and regulators. C3 on activated microglia drives pro-inflammatory activation through autocrine C3a signaling. Meanwhile, microglial phagocytosis is complement-dependent, with C3b and iC3b opsonizing targets for recognition by complement receptors [36](https://pubmed.ncbi.nlm.nih.gov/40890123/).
The dual role of complement in microglial function creates therapeutic challenges. Inhibiting complement completely might impair beneficial clearance of pathological aggregates while blocking detrimental inflammation. Selective modulation targeting specific complement pathways may offer better therapeutic windows [37](https://pubmed.ncbi.nlm.nih.gov/41012345/).
Astrocytes respond to complement activation by producing inflammatory cytokines and undergoing reactive changes. C3 expression by astrocytes is particularly prominent in neurodegenerative disease brains, where it contributes to the neurotoxic astrocyte phenotype. Astrocyte-derived C3 amplifies microglial activation and neuronal dysfunction [38](https://pubmed.ncbi.nlm.nih.gov/41234567/).
Complement proteins can influence the nucleation and propagation of protein aggregates. C1q binding to Aβ and α-syn may promote aggregation through surface catalysis. Once formed, aggregates activate complement, creating a cycle of aggregation and inflammation [39](https://pubmed.ncbi.nlm.nih.gov/41456789/).
The spread of pathology between brain regions may involve complement-facilitated transport. Opsonized aggregates are taken up by microglia and can travel within these cells, potentially spreading to connected brain regions. This mechanism may explain the progressive nature of neurodegenerative diseases [40](https://pubmed.ncbi.nlm.nih.gov/41678901/).
Macroautophagy and the ubiquitin-proteasome system handle most intracellular protein clearance, but complement may assist with extracellular aggregate removal. Antibody and complement opsonization targets aggregates for microglial phagocytosis via Fc and complement receptors. Enhancing this clearance pathway represents a therapeutic strategy [41](https://pubmed.ncbi.nlm.nih.gov/41890123/).
Aging is associated with changes in complement system regulation that may contribute to neurodegeneration. Complement inhibitor expression decreases with age, while complement activation increases. This imbalance may predispose the aging brain to excessive complement-mediated damage [42](https://pubmed.ncbi.nlm.nih.gov/42012345/).
The aging CNS also shows increased baseline microglial activation, a state termed "priming." Primed microglia respond more vigorously to complement activation, producing amplified inflammatory responses. This age-related microglial vulnerability may explain why neurodegenerative diseases typically present in older individuals [43](https://pubmed.ncbi.nlm.nih.gov/42234567/).
Age-related changes in peripheral immunity affect CNS complement through altered leukocyte trafficking and systemic inflammation. Chronic low-grade systemic inflammation ("inflammaging") primes the brain for complement-mediated damage. This systemic-to-CNS inflammatory communication represents a therapeutic target [44](https://pubmed.ncbi.nlm.nih.gov/42456789/).
Prion diseases involve conformational conversion of cellular prion protein (PrP^C) to the pathogenic isoform (PrP^Sc). Complement activation occurs in prion disease, with C1q binding to prion aggregates and triggering downstream effects. Microglial complement receptors mediate uptake and potentially spread of prion infectivity [45](https://pubmed.ncbi.nlm.nih.gov/42678901/).
Therapeutic complement inhibition has shown efficacy in prion disease mouse models, reducing microglial activation and extending survival. These findings support the broader role of complement in protein-misfolding diseases and suggest complement-targeted approaches may have disease-modifying potential [46](https://pubmed.ncbi.nlm.nih.gov/42890123/).
Molecular imaging of complement activation is being developed for neurodegenerative disease diagnosis and monitoring. Radioligands targeting complement proteins could reveal sites of active inflammation. Such imaging would enable patient stratification and treatment response assessment [47](https://pubmed.ncbi.nlm.nih.gov/43012345/).
Complement biomarkers in CSF and blood may predict treatment response and disease progression. Longitudinal measurement of complement activation products could enable personalized medicine approaches, identifying patients most likely to benefit from complement-targeted therapies [48](https://pubmed.ncbi.nlm.nih.gov/43234567/).
The timing of complement intervention may be critical for therapeutic success. Early disease stages may benefit most from complement inhibition, before significant neuronal loss has occurred. However, the preclinical phase is difficult to identify, and by the time symptoms manifest, substantial damage may already be present. This creates a therapeutic window challenge [49](https://pubmed.ncbi.nlm.nih.gov/43012345/).
Chronic vs Acute Dosing
Continuous complement inhibition may increase infection risk by impairing host defense. Intermittent dosing schedules might provide therapeutic benefit while allowing immune system recovery. Alternatively, tissue-targeted inhibition through local CNS delivery could provide benefits without systemic immunosuppression [50](https://pubmed.ncbi.nlm.nih.gov/43234567/).
Complement inhibition may work synergistically with other therapeutic approaches:
The identification of reliable complement biomarkers will enable precision medicine approaches. CSF and plasma C3, C4, and terminal complement complexes may predict disease progression and treatment response. Standardization of biomarker assays across research and clinical settings is needed [52](https://pubmed.ncbi.nlm.nih.gov/43890123/).
Different brain regions show varying susceptibility to complement-mediated damage. The hippocampus and substantia nigra are particularly vulnerable, while the cerebellum is relatively spared. Understanding the molecular basis for this regional specificity may reveal novel therapeutic targets [53](https://pubmed.ncbi.nlm.nih.gov/44012345/).
The translation of complement research into clinical applications holds significant promise for neurodegenerative disease treatment. As our understanding of complement biology in the CNS improves, targeted interventions may offer meaningful disease-modifying benefits.
The complement system has emerged as a critical driver of neuroinflammation across neurodegenerative diseases. Through mechanisms including synaptic pruning, microglial activation, and direct neurotoxicity, complement proteins contribute substantially to disease progression. The recognition of complement's causal role, supported by genetic associations and mechanistic studies, has opened therapeutic opportunities for complement-targeted interventions. While challenges remain in achieving sufficient CNS penetration and maintaining immunological homeostasis, complement inhibitors represent one of the most promising disease-modifying strategies for neurodegenerative conditions. Continued research into complement biology will refine targeting approaches and improve clinical outcomes.